Agenda
The website agenda is no longer being updated or used. Please refer to the Terrapinn Events App for the most recent version of agenda.
London, 17 - 18 March 2026
Schedule
Create your personal agenda –check the favourite icon
Mar 178:59
Conference pass
Welcome Remarks
Keynotes
Chris Shanks, Conference Director, Terrapinn Holdings Ltd
Mar 179:00
Conference pass
Chair’s Opening Remarks
Keynotes
Catherine Burns, BBC Health Correspondent, BBC News
Mar 179:05
Conference pass
Past, Present and Future of Gene Therapy: How far have we come?
Keynotes
Mar 179:25
Conference pass
Future-Proofing Your Supply Chain for Scalability: Aligning Early-Stage Decisions with Global Commercial Success
Keynotes
Alison Pritchard, Vice President - Business Development, EMEA-GBR, Cryoport Systems
Mar 179:45
Conference pass
Keynote Panel Discussion: Navigating the Cell and Gene Therapy Landscape: Opportunities & Challenges for Driving Market Success
Keynotes
Moderator: Mark Battaglini, Chief Strategy Officer, Alliance for Regenerative Medicine
Chris Williams, Chief Business Officer, Autolus
Peter Andersen, Chief Research & Development Officer, TREEFROG THERAPEUTICS
Claire Kerridge, Head of Gene Therapy, MHRA
Luke Henry, Chief Business Officer, Quell Therapeutics
Nan Zhang, Chief, Cell Therapy Manufacturing Section, Center for Cellular Engineering, National Institutes of Health
Shane Elder, Head of Global Market Access Strategy and Implementation, Europe, Canada, USA and China, AstraZeneca
Mar 1710:25
Conference pass
In vivo CAR-T: The manufacturing reality behind the promise
Keynotes
Davide Zocco, Head of Commercial Development Exosomes & mRNA-LNPs and Site Head, Lonza
Mar 1711:25
Conference pass
Chair’s Remarks: Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs
Evidence, Pricing & Access (Track 1)
Mar 1711:25
Conference pass
Chair's Remarks: Alain Wagner, Director of Research, CNRS
Immunotherapy (Track 5)
Alain Wagner, Director of Research, CNRS
Mar 1711:25
Conference pass
Chair's Remarks: Chris Baldwin, Vice President, Manufacturing and Supply, Resolution Therapeutics
Supply Chain & Logistics (Track 4)
Chris Baldwin, Vice President, Manufacturing & Supply, Resolution Therapeutics
Mar 1711:25
Conference pass
Chair's Remarks: Katie Binley, Chief Scientific Officer, ikarovec
Gene Therapy (Track 7)
Katie Binley, Chief Scientific Officer, ikarovec
Mar 1711:25
Conference pass
Chair's Remarks: Lara Campana, SVP, Research and Translational Science, Resolution Therapeutics
Innovation (Track 2)
Mar 1711:25
Conference pass
Chair's Remarks: Miguel Forte, CEO, Kiji Tx
Gene Modified Cell Therapy (Track 8)
Mar 1711:25
Conference pass
Chair's Remarks: Raphael G. Ognar, President & CEO, Co-founder, NKILT Therapeutics
Cell Therapy Sponsored by LICORbio (Track 3)
Mar 1711:25
Conference pass
Chair's Remarks: Ricardo Silva, Senior Scientist, iBET
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Mar 1711:25
Conference pass
Chair's Remarks: Roy Baynes, Executive Vice President and Chief Medical Officer, Eikon Therapeutics
Start-ups Showcase (Track 6)
Roy Baynes, Executive Vice President and Chief Medical Officer, Eikon Therapeutics
Mar 1711:25
Conference pass
Chair's Remarks: Sophie Mountcastle, Programme Manager, Medical Research Council
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Mar 1711:30
Conference pass
A not-for-profit approach to the pricing of an approved ex-vivo gene therapy
Evidence, Pricing & Access (Track 1)
Mar 1711:30
Conference pass
Behind Allogeneic Cell Therapy: The Critical Role of Donor Registries and the WMDA in Starting Material
Supply Chain & Logistics (Track 4)
Mar 1711:30
Conference pass
Building a scalable iPSC platform for the future
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Peter Andersen, Chief Research & Development Officer, TREEFROG THERAPEUTICS
Mar 1711:30
Conference pass
Building an academic pipeline
Innovation (Track 2)
Pamela Tranter, Head, Translational Research Group (TRO), University College London
Mar 1711:30
Conference pass
Cell therapy optimisation: Sourcing and engineering
Gene Modified Cell Therapy (Track 8)
Mar 1711:30
Conference pass
Engineering the biology of AAV secretion
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Darren Nesbeth, Associate Professor, University College London
Mar 1711:30
Conference pass
Gene therapy for kidney disease
Gene Therapy (Track 7)
Moin Saleem, Founder & CSO, Purespring Therapeutics
Mar 1711:30
Conference pass
Leveraging CIR technology to accelerate and improve access to off-the-shelf cell therapies for cancer patients
Cell Therapy Sponsored by LICORbio (Track 3)
Mar 1711:30
Conference pass
Mar 1711:30
Conference pass
Stop fighting your software: More Science, Less Admin
Start-ups Showcase (Track 6)
Digital transformation used to be a biotech buzzword, cited in strategic objectives, but not impacting daily life in the lab. Now laboratory software is a foundational element of most biotech discovery workflows. Yet for many bench scientists, finding a software system that’s easy and intuitive to use, affordable, actually reduces their administrative burden, and combines all the digital functionality they need into a single system is still a tall order.
Developed in response to existing product frustrations, Lab Thread combines an electronic laboratorynotebook, molecular biology tools and project management functionality alongside real-time inventory management. Featuringcollaborativechat functionality and AI-driven search, Lab Thread was built to simplifyteam communication, connecting multiple software modules into a single, auditable digital thread that continues to evolve in response to user needs.
Ryan Cawood, CEO, LabThread
Mar 1711:50
Conference pass
Creating sophisticated gene therapy solutions for chronic eye diseases
Gene Therapy (Track 7)
Katie Binley, Chief Scientific Officer, ikarovec
Mar 1711:50
Conference pass
CRISPR directed gene editing for lung cancer delivered via inhalation
Innovation (Track 2)
Eric Kmiec, Founder & CEO, CorriXR Therapeutics
Mar 1711:50
Conference pass
Digital models, shadows and twins for improving ATMP manufacturing
Gene Modified Cell Therapy (Track 8)
Joseph Egan, Research Associate, Teesside University
Mar 1711:50
Conference pass
Expansion of autologous regulatory T-cells for treatment of Idiopathic Aplastic Anaemia patients: Insights on the TIARA Trial
Immunotherapy (Track 5)
Nazia Matto, sATMP scientist, GMP Facility, Tower wing, Guys Hospital
Mar 1711:50
Conference pass
How to develop cell therapy programs in Latin America?
Cell Therapy Sponsored by LICORbio (Track 3)
Alejandro Madrigal, OBE FMedSci, Professor of Haematology, UCL Cancer Institute
Mar 1711:50
Conference pass
Operational considerations for cell therapy manufacturing
Supply Chain & Logistics (Track 4)
Mar 1711:50
Conference pass
Reinventing AAV & Lentiviral Purification with Smart Polymers
Start-ups Showcase (Track 6)
Mar 1711:50
Conference pass
Standardising process development for different cell therapy productions
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Mar 1711:50
Conference pass
The future of Advanced Therapies, a CDMO perspective
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Mar 1711:50
Conference pass
Update on the European and US Ecosystem for cell and gene therapies: What does the future of ATMP policy and access look like
Evidence, Pricing & Access (Track 1)
Mar 1712:10
Conference pass
Access timelines & Challenges for ATMPs and Oncology medicines in the Netherlands vs surrounding countries
Evidence, Pricing & Access (Track 1)
Peter Fassler, Director Market Access, Gilead Sciences
Mar 1712:10
Conference pass
Approaches to innate immunotherapy
Immunotherapy (Track 5)
Hugh JM Brady, Professor of Immunology, Imperial College London
Mar 1712:10
Conference pass
Going Digital in 120 Days: How Leaders in Cell & Gene Therapies Are Going Digital And Leveraging AI for Smarter Manufacturing
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
1. Fast-Track Digital Investment
Real-world strategies ATMP companies used tosecure board approval for digital projects.
How leading innovators linkregulatory readiness, operational risk, and ROI/ROAto unlock funding.
2. Playbooks from Top-Tier Cell & Gene Manufacturers
Blueprints for success: Proven digital deployment frameworks from CGT pioneers.
Avoiding common pitfalls:Real World Examples ofScalable Implementation in GMP and GxP Environments.
3. Smart Factories, Smarter Decisions: Unleashing AI on the Shop Floor
How AI istransforming batch record management, deviation analysis, and tech transfer.
From dashboards to decisions: Practical examples ofAI-driven insights in action from PD to commercial.
Mar 1712:10
Conference pass
In-Cell Western Assays as a Tool for Potency Evaluation in Drug Development
Cell Therapy Sponsored by LICORbio (Track 3)
Maria Ercu, Field Application Scientist, LI-COR Biosciences
Mar 1712:10
Conference pass
Keys to AAV manufacturing Success: Fast, robust and high-yield process development with DOE, Automated Bioreactors and selected critical raw materials
Gene Therapy (Track 7)
rAAVs are the preferred viral vector for gene therapy due to serotype-specific tropism, durable transgene expression and a growing number of approved and commercialized therapies. Manufacturers and developers are more than ever striving to simplify their manufacturing process whilst improving robustness and cost-effectiveness. Here we present a case study demonstrating the importance of selecting key critical raw materials such as transfection reagent FectoVIR®-AAV, and plasmid pPLUS®AAV-Helper for process performance, combined with a high-throughput production platform that integrates DOE with automated, single-use bioreactors to establish a scalable, high-yield rAAV upstream manufacturing platform suitable for preclinical and clinical supply.
Hakima Flici, Scientific Support Specialist, Sartorius
Mar 1712:10
Conference pass
Regenerative Macrophage Therapy for Inflammatory and Fibrotic Diseases
Gene Modified Cell Therapy (Track 8)
Bobby Zubis, Senior Director of Strategy & Operations, Resolution Therapeutics Ltd
Mar 1712:10
Conference pass
Surviving the valley of death: How can young companies succeed?
Start-ups Showcase (Track 6)
Mar 1712:10
Conference pass
Topic TBC
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Els Henckaerts, Professor, KU Leuven
Mar 1712:10
Conference pass
Turning rare disease data into actionable knowledge
Innovation (Track 2)
Flaminia Macchia, Chief Operating Officer, Orphanet-AISBL
Mar 1713:30
Conference pass
Chair’s Remarks: David Morrow, Scientific Lead for Advanced Therapies, EATRIS
Innovation (Track 2)
David Morrow, Scientific Lead for Advanced Therapies, EATRIS
Mar 1713:30
Conference pass
Chair’s Remarks: Nicola Redfern, Director, NJ Redfern Ltd.
Evidence, Pricing & Access (Track 1)
Nicola Redfern, Director, NJ Redfern Ltd.
Mar 1713:30
Conference pass
Chair's Remarks: Gerty Schreibelt, Assistant Professor / Immunologist, Radboud University Medical Centre
Immunotherapy (Track 5)
Gerty Schreibelt, Assistant Professor / Immunologist, Radboud University Medical Centre
Mar 1713:30
Conference pass
Chair's Remarks: Harris Makatsoris, Professor of Manufacturing, King’s College London
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Mar 1713:30
Conference pass
Chair's Remarks: Ivana Barbaric, Professor of Stem Cell Biology, The University of Sheffield
Cell Therapy Sponsored by LICORbio (Track 3)
Ivana Barbaric, Professor of Stem Cell Biology, University of Sheffield
Mar 1713:30
Conference pass
Chair's Remarks: Kerstin Papenfuss, Director Pharma, Deep Science Ventures
Start-ups Showcase (Track 6)
Kerstin Papenfuss, Director Pharma, Deep Science Ventures
Mar 1713:30
Conference pass
Chair's Remarks: Nisha Shaunak, Trust Head of Programmes, Advanced Therapies, Guy’s and St Thomas’ NHS Foundation Trust
Gene Therapy (Track 7)
Nisha Shaunak, Trust Head of Programmes, Advanced Therapies, Guy's & St Thomas' Nhs Foundation Trust
Mar 1713:30
Conference pass
Chair's Remarks: Patricia Longo, CMC Sr. Staff Scientist, Regeneron
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Patricia Longo, CMC Sr. Staff Scientist, Regeneron
Mar 1713:30
Conference pass
Chair's Remarks: Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics
Gene Modified Cell Therapy (Track 8)
Mar 1713:30
Conference pass
Chair's Remarks: Tara Sadeghi, Chief Operating Officer, Cellenkos Inc.
Supply Chain & Logistics (Track 4)
Tara Sadeghi, Chief Operating Officer, Cellenkos Inc.
Mar 1713:35
Conference pass
Clinical development of NK cell therapies
Cell Therapy Sponsored by LICORbio (Track 3)
Mar 1713:35
Conference pass
Comparability assessments for AAV process changes
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Patricia Longo, CMC Sr. Staff Scientist, Regeneron
Mar 1713:35
Conference pass
Engineering potent cellular therapies by modulating morphogenic signalling pathways
Gene Modified Cell Therapy (Track 8)
Mar 1713:35
Conference pass
In vivo generation of therapeutic immune cells: CAR-T and Beyond
Immunotherapy (Track 5)
David Peritt, Chief Scientific Officer, Lupagen
Mar 1713:35
Conference pass
New methods for detecting replication competent AAV for gene therapy
Gene Therapy (Track 7)
Mar 1713:35
Conference pass
Operational considerations of using cord blood as a cell therapy starting material
Supply Chain & Logistics (Track 4)
Alex Ross, Head of NHS Cord Bank, NHS Blood and Transplant
Mar 1713:35
Conference pass
Point of care manufacturing: Challenges & Opportunities
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Mar 1713:35
Conference pass
Resilience by Design: Alternative Financial Models for Funding
Start-ups Showcase (Track 6)
James Levine, President, Fondation Ipsen
Mar 1713:35
Conference pass
The bumpy and uncertain road to access in the Netherlands
Evidence, Pricing & Access (Track 1)
Henriette Burghoorn, Associate Director, Market Access, Gilead Sciences
Mar 1713:35
Conference pass
Where are we heading with exosomes?
Innovation (Track 2)
David Kuntin, CEO, Mesenbio
Mar 1713:55
Conference pass
ATMP commissioning in England: Latest insights
Cell Therapy Sponsored by LICORbio (Track 3)
Ben Doak, Head of Innovative Treatments, NHS England
Sarah McAleer, Pharmacy Lead, Innovative Treatments, NHS England
Mar 1713:55
Conference pass
CAR WARS – The rise of in vivo CAR-T
Start-ups Showcase (Track 6)
Adam Inche, Founder & CEO, Lentitek
Mar 1713:55
Conference pass
CAR-T therapy targeting solid cancers
Gene Therapy (Track 7)
Mar 1713:55
Conference pass
Engineering Armored CAR-T Cells to Overcome the Leukemic Microenvironment
Immunotherapy (Track 5)
Marta Serafini, Associate Professor, School of Medicine and Surgery, University of Milano-Bicocca
Mar 1713:55
Conference pass
HTAi insight: Rare disease interest group project
Evidence, Pricing & Access (Track 1)
Sheela Upadhyaya, Life Science Advisor in Rare Diseases, Openflex Ltd
Mar 1713:55
Conference pass
In vivo vs ex vivo manufacturing of lentiviral vectors – perspective born from experience
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Luca Alberici, Executive Vice President, Global Cell & Gene Technologies and General Manager, Milan Facility, AGC Biologics
Mar 1713:55
Conference pass
The imperative of institutional readiness in delivering CAR-T
Gene Modified Cell Therapy (Track 8)
Keith Wilson, Director, South Wales Blood and Marrow Transplant Programme, Cardiff and Vale University Health Board
Mar 1713:55
Conference pass
Three costly mistakes to avoid with your assay design when approaching clinical trials
Innovation (Track 2)
The Inserm We-Met platform, part of the French National Institute of Health and Medical Research, specializes in advanced functional biochemistry and high-resolution protein characterization. Leveraging cutting-edge technologies such as capillary electrophoresis and microfluidic systems, We-Met enables ultra-low sample consumption while maximizing analytical sensitivity and reproducibility—key parameters for robust assay development in clinical research.
This presentation will outline three high-impact errors that can compromise assay integrity and escalate costs in terms of time, resources, and sample availability:
- Sample Handling and Pre-Analytical Variability:From collection at investigator sites to biochemical extraction, improper sample preparation introduces systematic bias and jeopardizes downstream data quality.
- Reagent and Method Validation:Ensuring compliance with regulatory frameworks and guidelines such the ICH guideline M10 on bioanalytical method validation from EMA (European Medicine Agency) or FDA (U.S Food & Drug Administration), critical for assay reliability and regulatory acceptance.
- Quantification Accuracy and Reproducibility:Establishing rigorous controls for precision and reproducibility is essential to meet clinical trial standards and avoid costly rework.
Drawing on our experience in developing and validating complex assays—including one targeting a hexameric protein implicated in multiple sclerosis and post-COVID syndromes—we will provide a structured roadmap for mitigating these risks within an evolving regulatory landscape.
Mar 1713:55
Conference pass
Why commercialising CGT manufacturing is harder than it looks
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Mar 1714:15
Conference pass
CMC perspectives for supply of ATMPs
Supply Chain & Logistics (Track 4)
Ross Bunyan, External Manufacturing Lead, Resolution Therapeutics
Mar 1714:15
Conference pass
Development of a preventive dendritic cell vaccine for hereditary cancer
Immunotherapy (Track 5)
Gerty Schreibelt, Assistant Professor / Immunologist, Radboud University Medical Centre
Mar 1714:15
Conference pass
Development of mesenchymal stromal cell therapy for type 1 diabetes
Cell Therapy Sponsored by LICORbio (Track 3)
Mar 1714:15
Conference pass
Development of novel gene regulatory elements for CNS gene therapy
Gene Therapy (Track 7)
Mar 1714:15
Conference pass
Flexible evidence standards to improve access to cell therapies
Evidence, Pricing & Access (Track 1)
Adam PARNABY, Lead, Global Policy & Access, Bristol Myers Squibb
Mar 1714:15
Conference pass
Formulation and delivery of new modalities: Insight on viral formulation platforms
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Mar 1714:15
Conference pass
Gene modified cell therapy utilising gamma delta T-cells for the treatment of solid tumours
Gene Modified Cell Therapy (Track 8)
Daniel Fowler, Research Fellow, UCL
Mar 1714:15
Conference pass
Key learnings for developing a viable commercial strategy for young companies
Start-ups Showcase (Track 6)
Mar 1714:15
Conference pass
Manufacturing approaches for exosome therapeutics
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Dave Mentlak, Senior Scientist, Mesenbio
Mar 1714:15
Conference pass
Utilizing EU academic infrastructure for developing cell and gene therapies
Innovation (Track 2)
David Morrow, Scientific Lead for Advanced Therapies, EATRIS
Mar 1714:35
Conference pass
A Novel Cell‑Selective Lentiviral Platform for ex vivo and in vivo CAR‑T Engineering
Innovation (Track 2)
Mar 1714:35
Conference pass
Accelerating Advanced Therapies: Practical Solutions to Achieve Manufacturing Success
Gene Therapy (Track 7)
Mar 1714:35
Conference pass
Achieving a global approach to patient access for ATMPs and ultra-rare diseases
Evidence, Pricing & Access (Track 1)
Cem Zorlular, CEO, Er-Kim Pharmaceuticals
Mar 1714:35
Conference pass
From Millions of Cells to Your Next Immunotherapy Lead
Start-ups Showcase (Track 6)
Tobias Gamper, CEO, Avigen Ltd
Mar 1714:35
Conference pass
Monitoring of immune response with single cell technologies
Immunotherapy (Track 5)
Alain Wagner, Director of Research, CNRS
Mar 1714:35
Conference pass
Navigating tomorrow; Future proofing, resilience and risk mitigation in Cell and Gene Therapy Logistics
Supply Chain & Logistics (Track 4)
As the field of cell and gene therapies rapidly evolves, so too does the need for a robust logistics framework that ensures the safe and efficient delivery of these therapies to the patients whose lives depend on them. This presentation explores strategies for future proofing , resilience planning and risk mitigation in cell and gene therapy logistics. Key themes will include the importance of proactive contingency planning and risk mitigation, through enhancing collaboration among stakeholders at critical time points and the use of real time data analytics and advanced technologies. By fostering resilience in our logistics planning, we can mitigate risks associated with temperature sensitivity, regulatory compliance, supply chain variability and ultimately improve patient outcomes. Join us to discover actionable insights and best practices that can be applied to enable organizations to thrive in the dynamic environment of cell and gene therapies.
Mar 1714:35
Conference pass
On target biologic payload delivery using engineered gamma delta T-cells
Gene Modified Cell Therapy (Track 8)
Jonathan Fisher, Group Leader – Innate Immune Engineering Laboratory, University College London
Mar 1714:35
Conference pass
Presentation by Asimov
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Raja Srinivas, Cofounder, Asimov
Mar 1714:55
Conference pass
Application Tailored and Dissolvable Microcarrier for large-scale adherent cell and exosome manufacturing
Start-ups Showcase (Track 6)
Mar 1714:55
Conference pass
Engineering Optimized AAV Capsids via AI-Guided In Silico Design
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Hugh O'Brien, CTO, Lir Therapeutics
Mar 1714:55
Conference pass
From uncertainty to insight: real-world evidence of advanced therapies in Wales
Evidence, Pricing & Access (Track 1)
Hannah Crocker, Advanced Therapies Outcomes Manager, NHS Wales Joint Commissioning Committee (NWJCC)
Mar 1714:55
Conference pass
Maintaining Genomic Integrity in Human Pluripotent Stem Cells for Advanced Therapies
Cell Therapy Sponsored by LICORbio (Track 3)
Ivana Barbaric, Professor of Stem Cell Biology, University of Sheffield
Mar 1714:55
Conference pass
Panel Discussion: Harnessing Technological Innovation to Optimise Supply Chain and Logistics in Advanced Therapies
Supply Chain & Logistics (Track 4)
Holly Garlick, Head of GMP, Gene Therapy Innovation & Manufacturing Centre, University of sheffield
Owen Bain, Director, Centre for Cell Gene Tissue Therapeutics, Royal Free NHS Trust
Ketki Vispute, Associate Director, Manufacturing, Autolus
Alison Pritchard, Vice President - Business Development, EMEA-GBR, Cryoport Systems
Moderator: Tara Sadeghi, Chief Operating Officer, Cellenkos Inc.
Mar 1714:55
Conference pass
Stem cell derived macrophages for next-gen immunotherapies
Gene Modified Cell Therapy (Track 8)
Nico Lachmann, Professor, Hannover Medical School
Mar 1714:55
Conference pass
The Extroducer and targeted delivery of clinical payloads: case studies
Innovation (Track 2)
Ricardo Baptista, Chief Technology Officer, Smartcella
Mar 1714:55
Conference pass
The impact of the new Point of Care and Modular manufacturing regulation on ATMP delivery in the UK
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Mar 1714:55
Conference pass
Update from Genethon: Applications of technological platforms
Gene Therapy (Track 7)
Angela Columbano, Head Business Development and Partnership, Genethon
Mar 1714:55
Conference pass
Use of CAR-T Regs for the treatment of autoimmunity and transplantation
Immunotherapy (Track 5)
Marc Martinez-Llordella, Founder and VP Biology, Quell Therapeutics
Mar 1715:15
Conference pass
A global vision for cell and gene therapy
Cell Therapy Sponsored by LICORbio (Track 3)
Mar 1715:15
Conference pass
Delivering the first Gene Therapy as standard of care in Wales
Gene Therapy (Track 7)
Samya Gwen Obaji, Consultant Haematologist, Adult Lead and Co-Director of the Cardiff Haemophilia Centre, Cardiff and Vale University Health Board
Mar 1715:15
Conference pass
Development and Translation of TCR Immunogene Therapy for Cancer
Gene Modified Cell Therapy (Track 8)
Shao-An Xue, Professor, Zhengzhou University of Technology
Mar 1715:15
Conference pass
Leveraging collaborative efforts to address market access & HTA obstacles
Evidence, Pricing & Access (Track 1)
Josie Godfrey, Independent Market Access and Rare Disease Adviser, Independent Rare Disease Expert
Mar 1715:15
Conference pass
Multi-Modal Assays for High-Precision Translational and Regulatory Decision-Making in CGT
Innovation (Track 2)
George Dorfman, Global Director, Cell & Gene Therapy, Mission Bio
Mar 1715:15
Conference pass
Navigating the complex journey of cell therapy manufacturing from lab to patient: the role of automated platforms
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Stephanie Bourin, Senior Product Manager, Cytiva
Mar 1715:15
Conference pass
Presentation by 4basebio
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Milena Pavlickova, Associate Director of Platform Development, 4basebio
Mar 1716:05
Conference pass
Chair’s Remarks: Paolo Morgese VP Public Affairs, Europe, Alliance for Regenerative Medicine
Evidence, Pricing & Access (Track 1)
Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
Mar 1716:05
Conference pass
Chair's Remarks: Andrew Palfreeman, Associate Director, R&D Lab Core & Operations, Quell Therapeutics Ltd
Innovation (Track 2)
Andrew Palfreeman, Associate Director, R&D Lab Core and Operations, Quell Therapeutics
Mar 1716:05
Conference pass
Chair's Remarks: Arsalan Wafi, Academic Clinical Lecturer, King's College London
Cell Therapy Sponsored by LICORbio (Track 3)
Arsalan Wafi, Academic Clinical Lecturer, King´s College London
Mar 1716:05
Conference pass
Chair's Remarks: Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan
Immunotherapy (Track 5)
Mar 1716:05
Conference pass
Chair's Remarks: Elena Beltrami, Investment Manager, Biotech Venture Advisors
Start-ups Showcase (Track 6)
Mar 1716:05
Conference pass
Chair's Remarks: Michelle Levene, Managing Director, 161 Consulting
Patient Engagement & Delivery (Track 4)
Michelle Levene, Managing Director, 161 Consulting Ltd
Mar 1716:05
Conference pass
Chair's Remarks: Miguel Forte, CEO, Kiji Tx
Gene Modified Cell Therapy (Track 8)
Mar 1716:05
Conference pass
Chair's Remarks: Paul Carter, Senior Director, MSAT, Quell Therapeutics Ltd
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Paul Carter, Senior Director, MSAT, Quell Therapeutics
Mar 1716:05
Conference pass
Chair's Remarks: Paulo Fernandes, Senior Director, Technical Operations, Spur Therapeutics
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Paulo Fernandes, Senior Director, Technical Operations, Spur Therapeutics
Mar 1716:05
Conference pass
Chair's Remarks: Uta Griesenbach, Professor, National Heart And Lung Institute, Imperial College
Gene Therapy (Track 7)
Uta Griesenbach, Professor of Molecular Medicine, Imperial College London
Mar 1716:10
Conference pass
Academic proposal for market authorization of CAR-T cells
Gene Modified Cell Therapy (Track 8)
Mar 1716:10
Conference pass
Bridging discovery with development: Transitioning into a clinical biotech
Start-ups Showcase (Track 6)
Harry Kwong, Director, Portfolio Management, Complement Therapeutics
Mar 1716:10
Conference pass
Delivering Market-Responsive Capability for Early Phase and Advanced Clinical Development
Patient Engagement & Delivery (Track 4)
The NIHR is taking decisive action to gain ground internationally in early-phase delivery, advancedmodalities. Hear plans to enhance our research delivery capability to execute the most advanced, complex and high-value commercial studies at pace—and to pivot that capability as science, pipelines and population need change. With a specific focus on early-phase and advanced modalities, vaccines and immune therapies, and oncology, learn how we are accelerating innovation and aligning our national research delivery capability to global drug-development trends and NHS unmet clinical need.
Maria Koufali, Life Sciences Industry Director, NIHR
Mar 1716:10
Conference pass
Developing a reference material to enable accurate and reliable detection of residual pluripotent stem cells in pluripotent stem cell derived mesenchymal stromal cell therapy products
Cell Therapy Sponsored by LICORbio (Track 3)
Luke Lindsay-Hill, Head of Cell Therapy, Biotherapeutics Advanced Therapies, MHRA
Mar 1716:10
Conference pass
Developing muscle specific gene therapy for rare neuromuscular disorders
Innovation (Track 2)
Annalucia Darbey, Postdoctoral Research Fellow, University College London
Mar 1716:10
Conference pass
Evidence and Access challenges for CAR-T therapies across Europe
Evidence, Pricing & Access (Track 1)
Brett Doble, Senior Director, RWE & HEOR - Multiple Myeloma, Kite, a Gilead Company
Mar 1716:10
Conference pass
Exploring the challenges of delivering immunotherapies at clinical sites
Immunotherapy (Track 5)
Mar 1716:10
Conference pass
Scouting for innovative gene & cell therapies
Gene Therapy (Track 7)
Mar 1716:10
Conference pass
State of industry for manufacturing of ATMPs in the UK
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Siddharth Subramaniam, Senior Policy and Public Affairs Executive, BIA
Mar 1716:10
Conference pass
Suspension process for LVV manufacturing
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Chrysanthi Sitmalidou, Scientist II, Orchard Therapeutics
Mar 1716:30
Conference pass
ADC release mechanisms at the tumour
Immunotherapy (Track 5)
Marc de la Roche, Asst. Professor, Dept. of Biochemistry, University of Cambridge
Mar 1716:30
Conference pass
CAR finder technology for rapid cell therapy development
Start-ups Showcase (Track 6)
Mar 1716:30
Conference pass
Considering launch in Rest of World? What to look out for in pricing and access beyond core markets
Evidence, Pricing & Access (Track 1)
Pedro Borga, Associate Director, Market Access and Pricing, Amicus Therapeutics
Mar 1716:30
Conference pass
Developing gene therapy for metabolic diseases
Gene Therapy (Track 7)
Leila Zeinab Asgarian, Senior Research Fellow, UCL
Mar 1716:30
Conference pass
Engineered bacteria to enhance immunotherapy responses
Gene Modified Cell Therapy (Track 8)
Pedro Correa de Sampaio, CEO, Neobe Therapeutics
Mar 1716:30
Conference pass
IMPACT: Irish Medicines Centre for Personalised Advanced Cellular Therapeutics
Cell Therapy Sponsored by LICORbio (Track 3)
Athanasios (Sakis) Mantalaris, Professor, Trinity College Dublin
Mar 1716:30
Conference pass
Successful upscaling strategies in adenovirus manufacturing
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Mar 1716:30
Conference pass
The Safety Journey for Advanced Therapies – Innovation Over Effort
Innovation (Track 2)
Objectives:
- Recognise why traditional pharmacovigilance models are often poorly aligned with the realities of advanced therapies.
- Understand where safety activities can create disproportionate effort without improving compliance or data accuracy.
- Evaluate how innovation-led approaches, including automation and streamlined workflows, can support complex modalities and small, diverse patient populations.
- Take away practical considerations for building scalable, compliant safety frameworks across the product lifecycle long-term.
Abstract:
Advanced therapies are redefining what good patient safety oversight looks like. Novel mechanisms of action, long-term risk potentials and limited clinical exposure place pressure on pharmacovigilance models that were built for products having a pharmacological activity, whilst regulatory expectations are evolving to accommodate such new scientific breakthroughs.
This session follows the safety journey of advanced therapies and challenges the assumption that stronger oversight requires more intense effort. Instead, it explores how innovation-led approaches, including automation, smarter workflows, and proportionate safety design can simplify operations, strengthen compliance, enhance data accuracy and support accelerated development without compromising patient safety.
Mar 1716:30
Conference pass
Trials and tribulations of setting up a ultra-rare diseases charity
Patient Engagement & Delivery (Track 4)
Mar 1716:50
Conference pass
Barriers to diagnosis: Using data to unlock better access to healthcare
Patient Engagement & Delivery (Track 4)
Samantha Barber, Chief Executive Officer, Gene People
Mar 1716:50
Conference pass
Considerations for QC programme development in cell therapies
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Mar 1716:50
Conference pass
Developing innovative cell therapies for solid tumours and autoimmune diseases in resource-constrained settings
Gene Modified Cell Therapy (Track 8)
Mar 1716:50
Conference pass
Developing technology for the long-term preservation of biologics
Innovation (Track 2)
Olivier Tramis, Senior Research Scientist, University of Strasbourg
Mar 1716:50
Conference pass
Development of iPSC derived CAR-NK Cells for Immunotherapy
Immunotherapy (Track 5)
Marina Tarunina, Research Director, Plasticell
Mar 1716:50
Conference pass
From start-up to a publicly traded company
Start-ups Showcase (Track 6)
Mar 1716:50
Conference pass
Integrated continuous biomanufacturing of AAVs
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Mar 1716:50
Conference pass
Latest update on Joint Clinical Assessments
Evidence, Pricing & Access (Track 1)
Matias Olsen, Senior Manager, Public Affairs & Policy, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Mar 1716:50
Conference pass
Next generation gene writing platform for cell & gene therapies
Gene Therapy (Track 7)
Mar 1716:50
Conference pass
Shaping the Future of Regenerative Medicine: Unlocking the potential of allogenic therapies
Cell Therapy Sponsored by LICORbio (Track 3)
Kristian Tryggvason, Chief Executive Officer, Alder Therapeutics
Mar 1717:10
Conference pass
A novel ex vivo engineered monocyte-based therapy for peripheral arterial disease
Gene Modified Cell Therapy (Track 8)
Ashish Patel, Reader in Vascular Surgery, Consultant Vascular Surgeon, King’s College London & Guy’s and St Thomas’ Hospital NHS Foundation Trust
Mar 1717:10
Conference pass
Antibody engineering to account for the tumour interface with the immune macroenvironment
Immunotherapy (Track 5)
Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy, King's College London
Mar 1717:10
Conference pass
Exploring the regulatory challenges delivering cell and gene therapies in the NHS
Cell Therapy Sponsored by LICORbio (Track 3)
Mar 1717:10
Conference pass
Industrialization of iPSC-Derived Allogeneic Cell Therapies: Challenges and Breakthroughs?
Innovation (Track 2)
Induced pluripotent stem cell (iPSC)–derived allogeneic immune cell therapies are poised to transform immuno-oncology, but broad adoption depends on scalable, reproducible, and cost-efficient manufacturing. This presentation highlights the industrialization of iPSC-derived NK and T-cell therapies through Cellistic’s Echo™-NK and Echo™-T manufacturing platforms.
Echo™-NK and Echo™-T address key limitations of donor-derived and autologous approaches by enabling standardized, closed, and automated bioprocesses that support consistent product quality and predictable performance from early development through commercial scale. High-density expansion and robust differentiation workflows significantly reduce manufacturing complexity and cost of goods while maintaining stringent quality attributes. Integrated control strategies ensure consistent identity, potency, and regulatory readiness. Together, these platforms enable the transition from bespoke cell therapy manufacturing to industrialized, commercially viable allogeneic immunotherapies.
www.cellistic.com
Mar 1717:10
Conference pass
Operationalizing Patient Engagement in Gene Therapy Development
Gene Therapy (Track 7)
Mary Wang, Director, Patient Engagement, Genespire
Mar 1717:10
Conference pass
Realising the value of patient & public involvement
Patient Engagement & Delivery (Track 4)
Mar 1717:10
Conference pass
Trends in access barriers for advanced therapies in the UK
Evidence, Pricing & Access (Track 1)
Mar 1717:30
Conference pass
Panel Discussion: Advancing Cell Therapy Manufacturing: Embracing AI, Automation and Digitalisation
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Ross Bunyan, External Manufacturing Lead, Resolution Therapeutics
Joseph Egan, Research Associate, Teesside University
Jorge Salazar, Senior Scientist, INmune Bio
Nan Zhang, Chief, Cell Therapy Manufacturing Section, Center for Cellular Engineering, National Institutes of Health
Mathias Svahn, Chief Executive Officer, NextCell Pharma
Ran Tsalic, Business Development Manager UK, Aldevron
Mar 1717:30
Conference pass
Panel Discussion: Broader Applications for Gene Therapies
Gene Therapy (Track 7)
Moderator: Uta Griesenbach, Professor of Molecular Medicine, Imperial College London
Salmaan Dalvi, Chief Executive Officer, Global Regenerative Medicine Society
Azadeh Kia, VP Gene Therapy Research, Beacon Therapeutics
Alison Clare, Senior Research Associate, University of Bristol
Samantha Barber, Chief Executive Officer, Gene People
Mar 1717:30
Conference pass
Panel Discussion: Engaging with Patients to Improve Access and Affordability
Patient Engagement & Delivery (Track 4)
Moderator: Michelle Levene, Managing Director, 161 Consulting Ltd
Sonia Valero, Head Of Clinical Operations - Patient Advocacy Leader, Vivet Therapeutics
Katja Berg, Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU, AstraZeneca
Cem Zorlular, CEO, Er-Kim Pharmaceuticals
Josie Godfrey, Independent Market Access and Rare Disease Adviser, Independent Rare Disease Expert
Mar 1717:30
Conference pass
Panel Discussion: Exploring the Evolving Landscape of Viral Vector Manufacturing
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Moderator: Simon Briggs, Director Advanced Analytics, Orchard Therapeutics
Holger Laux, Director of Genetic Medicine, CSL Behring
Darren Nesbeth, Associate Professor, University College London
Sujith Sebastian, Viral Vector Hub Manager, Clinical Biotechnology Centre, NHSBT
Toby Gamlen, Head of Manufacturing, Gene Therapy Innovation and Manufacturing Centre, University of sheffield
Killian Hanlon, CEO, Lir Therapeutics
Giuliana Vallanti, Senior VP Operations & Global R&D CGT, AGC Biologics
Mar 1717:30
Conference pass
Panel Discussion: Exploring the Latest Challenges and Opportunities for Cell Therapies
Cell Therapy Sponsored by LICORbio (Track 3)
Moderator: David Kuntin, CEO, Mesenbio
Alejandro Madrigal, OBE FMedSci, Professor of Haematology, UCL Cancer Institute
Arsalan Wafi, Academic Clinical Lecturer, King´s College London
Tara Sadeghi, Chief Operating Officer, Cellenkos Inc.
Mar 1717:30
Conference pass
Panel Discussion: New Frontiers in Cell Therapy: In-Vivo Engineering
Gene Modified Cell Therapy (Track 8)
Moderator: David Peritt, Chief Scientific Officer, Lupagen
Nico Lachmann, Professor, Hannover Medical School
Ash Toye, Professor of Cell Biology, University of Bristol & Co-founder, Scarlet Therapeutics, University of Bristol
Mar 1717:30
Conference pass
Panel Discussion: Opportunities and Challenges of Investing in ATMPs: Insight on the Latest European and Global Trends
Innovation (Track 2)
Moderator: Sven Kili, Partner, Saisei Ventures
Owen Smith, Partner, 4BIO CAPITAL
Kristian Tryggvason, Chief Executive Officer, Alder Therapeutics
Pedro Correa de Sampaio, CEO, Neobe Therapeutics
Leigh Brody, Investor, AlbionVC
Andrew Roddam, Chief Business Development Officer, Everyone medicines
Mar 1717:30
Conference pass
Panel Discussion: Perspectives on the EU Joint Health Technology Assessment: Is the JCA fit for purpose?
Evidence, Pricing & Access (Track 1)
Moderator: Matias Olsen, Senior Manager, Public Affairs & Policy, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Henriette Burghoorn, Associate Director, Market Access, Gilead Sciences
Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
Brett Doble, Senior Director, RWE & HEOR - Multiple Myeloma, Kite, a Gilead Company
Mar 1717:30
Conference pass
Panel Discussion: Revolutionising Cancer Treatment: Innovations in Immunotherapy
Immunotherapy (Track 5)
Marc de la Roche, Asst. Professor, Dept. of Biochemistry, University of Cambridge
Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy, King's College London
Shao-An Xue, Professor, Zhengzhou University of Technology
Mar 1717:30
Conference pass
Panel Discussion: Top Tips for Attracting Investment
Start-ups Showcase (Track 6)
Victor Hernandez, CSO, Axovia therapeutics
Kerstin Papenfuss, Director Pharma, Deep Science Ventures
Create your personal agenda –check the favourite icon
Mar 189:00
Conference pass
Chair’s Opening Remarks
Keynotes
Nick France, Vice President, Head: Genomic Medicine Development Unit, Alexion, AstraZeneca Rare Disease
Mar 189:05
Conference pass
The Day After: Turning Headlines into Value in Biotech M&A
Keynotes
Joshi Venugopal, Global Head Drug Development Operation Ex, Novartis
Mar 189:25
Conference pass
Where are we heading with AI for Cell and Gene Therapies?
Keynotes
Nick France, Vice President, Head: Genomic Medicine Development Unit, Alexion, AstraZeneca Rare Disease
Mar 189:45
Conference pass
Delivering next generation regenerative medicine through bioengineering
Keynotes
Mar 1810:05
Conference pass
Fireside Chat: The first successful treatment of Huntington’s disease with a gene therapy
Keynotes
Edward Wild, Professor of Neurology, UCL Huntington’s Disease Centre
Interviewer: Ashleigh Furlong, Health reporter, Bloomberg News
Mar 1811:05
Conference pass
Chair's Remarks: Adam Brown, Associate Professor, The University of Sheffield
Start-ups Showcase (Track 6)
Mar 1811:05
Conference pass
Chair's Remarks: Amanda-Jayne Carr, Associate Professor, UCL Institute of Ophthalmology
Cell Therapy Sponsored by LICORbio (Track 3)
Mar 1811:05
Conference pass
Chair's Remarks: David James, Professor of Bioengineering, Sheffield University
Innovation (Track 2)
David James, Emeritus Professor of Bioprocess Engineering, University of sheffield
Mar 1811:05
Conference pass
Chair's Remarks: Gaurav Bhavsar, Technical Director, Gene Therapy Vector Facility (GTVF), King’s College London
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Gaurav Bhavsar, Technical Director, Gene Therapy Vector Facility (GTVF), King's College London
Mar 1811:05
Conference pass
Chair's Remarks: Giorgia Santilli, Associate Professor in Gene Therapy, UCL Great Ormond Street Institute of Child Health
Gene Therapy (Track 7)
Giorgia Santilli, Associate Professor, UCL
Mar 1811:05
Conference pass
Chair's Remarks: Heather Main, Co-founder, HOYA Consulting
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Heather Main, Co-Founder, HOYA Consulting
Mar 1811:05
Conference pass
Chair's Remarks: Marcello Maresca, Senior Director - Genome Engineering, AstraZeneca
Gene Modified Cell Therapy (Track 8)
Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca
Mar 1811:05
Conference pass
Chair's Remarks: Reuben Benjamin, Clinical Senior Lecturer, King's College London
Clinical Development (Track 4)
Reuben Benjamin, Clinical Senior Lecturer, King's College London
Mar 1811:05
Conference pass
Chair's Remarks: Roberto Nitsch, Director, AstraZeneca
Gene Editing (Track 5)
Roberto Nitsch, Director, AstraZeneca
Mar 1811:05
Conference pass
Chair's Remarks: Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Regulation (Track 1)
Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Mar 1811:10
Conference pass
AAV platform process development
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Gaurav Bhavsar, Technical Director, Gene Therapy Vector Facility (GTVF), King's College London
Mar 1811:10
Conference pass
Achieving early-stage clinical success
Clinical Development (Track 4)
Mar 1811:10
Conference pass
Drug screening for HDR
Gene Editing (Track 5)
Anna-Lina Cavallo, Director Discovery Cell and Gene Therapy integrated Bioanalysis, AstraZeneca
Mar 1811:10
Conference pass
From idea to reality: How do you spin out a new cell therapy platform?
Start-ups Showcase (Track 6)
Ash Toye, Professor of Cell Biology, University of Bristol & Co-founder, Scarlet Therapeutics, University of Bristol
Mar 1811:10
Conference pass
Global manufacturing footprint from build to commercial scale-up
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Sarah Snykers, Head of Operations, Legend Biotech
Mar 1811:10
Conference pass
Improving Prime Editing Repair Outcomes by DNA Repair Modulation
Gene Modified Cell Therapy (Track 8)
Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca
Mar 1811:10
Conference pass
Neurosurgical delivery of ATMPs to human brain in early-phase first in-human clinical trials
Gene Therapy (Track 7)
Mar 1811:10
Conference pass
Putting the patient front and centre: Delivering on the promise of cell therapies
Cell Therapy Sponsored by LICORbio (Track 3)
Mar 1811:10
Conference pass
Regulatory update on ATMPs: Adapting to the evolving landscape
Regulation (Track 1)
Amina Al-Mossawi, Qualified Person, MeiraGTx
Mar 1811:10
Conference pass
Treating 1 in 2500: Tackling diseases of the peripheral nervous system
Innovation (Track 2)
Mar 1811:30
Conference pass
Advancing In Vivo CAR-T Therapies: CDMO Strategies Integrating LVV Delivery and mRNA-tLNP Platforms
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Mar 1811:30
Conference pass
Beyond the protocol: Setting yourself up for clinical trial success
Clinical Development (Track 4)
Mar 1811:30
Conference pass
Decentralized Manufacturing of ATMPs: Navigating Regulatory Innovations and Strategic Partnerships for Enhanced Patient Care
Regulation (Track 1)
In the dynamic realm of healthcare regulation, economic and innovative drives are increasingly linked, prompting regions like the US, EU, and UK to seek independence and enhance their biomedical appeal through supportive regulations. A significant advancement is the UK's 2025 implementation of a framework for decentralized manufacturing of Advanced Therapy Medicinal Products (ATMPs) near the point of care, ensuring timely patient access. This model connects localized units to a central "Mothership" site, though approval is needed when centralized methods are impractical, limiting immediate benefits for many ATMPs.
Transforming manufacturing and testing protocols is vital to meet new demands, with closed-system manufacturing and rapid microbial testing becoming essential for modular environments. The handling of raw materials, including off-the-shelf options like cell culture media and cytokines, impacts decentralized technology implementation. Automation and computerized data analysis are crucial, placing more responsibility on manufacturers, particularly the Qualified Person (QP), to ensure compliance and efficacy.
Strategic partnerships are vital to support centralized and decentralized manufacturing. Companies like Sartorius offer technological innovations and comprehensive support, helping navigate regulatory complexities and optimize processes. Such partnerships enable manufacturers to adapt to regulatory changes, enhance production capabilities, and efficiently deliver advanced therapies to patients despite potential regulatory delays in regions like the EU and US.
Ravid Grimberg, Head of Regulatory Compliance and Risk Management, Sartorius
Mar 1811:30
Conference pass
Evolution of gene therapy for inherited immune disorders
Gene Therapy (Track 7)
Giorgia Santilli, Associate Professor, UCL
Mar 1811:30
Conference pass
From Causes to Consequences: Decoding Off‑Target Events in CRISPR Gene Editing using INDUCE-seq
Gene Editing (Track 5)
- Unbiased, genome-wide mapping of gene-editing–induced DNA breaks using INDUCE-seq, a PCR-free, cell-based assay with single-nucleotide resolution.
- INDUCE-seq accelerates discovery and preclinical decision-making by delivering high signal-to-noise, reproducible on- and off-target data in days, not weeks, across therapeutically relevant cell types.
- Enables earlier de-risking of gene-editing programs, with data that supports guide selection, modality comparisons, and emerging regulatory expectations for genome integrity.
Mar 1811:30
Conference pass
GMP-compliant up-scaling of an optimized feeder-free CAR NK cell expansion protocol
Cell Therapy Sponsored by LICORbio (Track 3)
Anna Duenkel, Head of GMP Development Unit, Fraunhofer IZI
Mar 1811:30
Conference pass
Matrix production for cell and gene therapies
Innovation (Track 2)
Mar 1811:30
Conference pass
Modified cell therapies to overcome solid tumours
Gene Modified Cell Therapy (Track 8)
Jonathan Sumner, Associate Principal Scientist, AstraZeneca
Mar 1811:30
Conference pass
Reducing CMC risks and ensuring process scalability for Phase 3 readiness of vididencel, a cell-based active immunotherapy for myeloid blood cancers - Case study co-presented by Mendus & NorthX Biolog
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Cecilia Wingenblixt, Project Manager, NorthX Biologics
Anneke Reurs, Director CMC/process development, Mendus
Mar 1811:30
Conference pass
Scaling-up start-ups towards clinical trials
Start-ups Showcase (Track 6)
Alicia El Haj, Director, Institute of Translational Medicine, University of Birmingham
Mar 1811:50
Conference pass
Autologous and allogenic CAR-Ts for haematological and solid tumours
Gene Modified Cell Therapy (Track 8)
Mar 1811:50
Conference pass
Developing therapeutics oligonucleotides for reactivating genes
Gene Therapy (Track 7)
Vikash Reebye, Gene Activation Therapeutics Lead, Imperial College London
Mar 1811:50
Conference pass
Development of skills and training resources: Insight from the Innovation Hub for Gene Therapy
Innovation (Track 2)
Janine Kirby, Professor, University of sheffield
Mar 1811:50
Conference pass
Enabling high-throughput production of uniform cell aggregates by harnessing in-air microfluidics
Start-ups Showcase (Track 6)
Mar 1811:50
Conference pass
Exosomes for targeted drug delivery: Unlocking the potential of gene editing complexes
Gene Editing (Track 5)
Samantha Thomas, Head of Research, ReNeuron
Mar 1811:50
Conference pass
Lentiviral Vector Manufacturing
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Mar 1811:50
Conference pass
Regulatory Approval & Quality Assessment of ATMPs
Regulation (Track 1)
Janet Glassford, Expert Quality Assessor, Biologicals Unit, Medicines & Healthcare products Regulatory Agency
Mar 1811:50
Conference pass
Stem cell application in musculoskeletal disorders
Clinical Development (Track 4)
Inês Leal Reis, Co-founder, Regenera
Mar 1811:50
Conference pass
Stem cell derived extracellular vesicles as a substitute for cell therapy
Cell Therapy Sponsored by LICORbio (Track 3)
Mar 1811:50
Conference pass
The master file model for qualifying materials
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Heather Main, Co-Founder, HOYA Consulting
Mar 1812:10
Conference pass
A unique immuno-modulatory platform to rejuvenate immune competence & overcome treatment resistance
Cell Therapy Sponsored by LICORbio (Track 3)
Alex Blyth, Founder & CEO, Lift Biosciences Ltd
Mar 1812:10
Conference pass
Analytical methods for oncolytic viruses and their use to elucidate structure function relations
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Johannes Solzin, Laboratory Head, Analytical Development, ATMPs, Boehringer Ingelheim
Mar 1812:10
Conference pass
Can Europe compete? What the EU Biotech Act delivers for the ATMP industry
Innovation (Track 2)
Mar 1812:10
Conference pass
Cell free stem cell therapy 2.0: Clinical potential of MSC-EVs
Start-ups Showcase (Track 6)
Bernd Giebel, Professor, University Hospital Essen
Mar 1812:10
Conference pass
Challenges and strategies for the development of a bicistronic AAV gene therapy for ocular disorders
Gene Therapy (Track 7)
Emily Warner, VP, Technical Operations, ikarovec
Mar 1812:10
Conference pass
Critical considerations for successful ATMP development: Academic bench to commercial bedside
Clinical Development (Track 4)
Mar 1812:10
Conference pass
How to create the optimal immune milieu for optimal effect Immune Effector Cells
Gene Modified Cell Therapy (Track 8)
Mar 1812:10
Conference pass
Increasing Your Chance of Approval: Learning from Past Mistakes
Regulation (Track 1)
Mar 1812:10
Conference pass
Quality control considerations in iPSC gene editing
Gene Editing (Track 5)
Pia Johansson, Director, Cell and Gene Technologies Core, Lund University
Mar 1812:10
Conference pass
Scaling cell therapies for cardiac and neurologic diseases
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Mar 1813:30
Conference pass
Chair's Remarks: Adam Brown, Associate Professor, The University of Sheffield
Start-ups Showcase (Track 6)
Mar 1813:30
Conference pass
Chair's Remarks: Heather Main, Co-founder, HOYA Consulting
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Heather Main, Co-Founder, HOYA Consulting
Mar 1813:30
Conference pass
Chair's Remarks: Leila Abbas, Preclinical Lead, Rinri Therapeutics
Clinical Development (Track 4)
Leila Abbas, Preclinical Lead, Rinri Therapeutics
Mar 1813:30
Conference pass
Chair's Remarks: Manal Mohammed, Senior Lecturer (Medical Microbiology), University of Westminster
Innovation (Track 2)
Manal Mohammed, Senior Lecturer (Medical Microbiology), University of Westminster
Mar 1813:30
Conference pass
Chair's Remarks: Marcello Maresca, Senior Director - Genome Engineering, AstraZeneca
Gene Modified Cell Therapy (Track 8)
Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca
Mar 1813:30
Conference pass
Chair's Remarks: Patrick Hopkinson, Independent HTA Expert
Cell Therapy Sponsored by LICORbio (Track 3)
Mar 1813:30
Conference pass
Chair's Remarks: Piers Walser, Research Scientist, Clinical Biotechnology Centre, NHS Blood and Transplant
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Piers Walser, Lead Development Scientist, Clinical Biotechnology Centre, NHSBT
Mar 1813:30
Conference pass
Chair's Remarks: Roberto Nitsch, Director, AstraZeneca
Gene Editing (Track 5)
Roberto Nitsch, Director, AstraZeneca
Mar 1813:30
Conference pass
Chair's Remarks: Sara Benedetti, Group Leader, Assistant Professor in Gene Therapy, UCL
Gene Therapy (Track 7)
Sara Benedetti, Group Leader, Assistant Professor in Gene Therapy, University College London
Mar 1813:30
Conference pass
Chair's Remarks: Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Regulation (Track 1)
Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Mar 1813:35
Conference pass
Compassionate Use and Transition of Care for Paediatric Patients
Clinical Development (Track 4)
Hamza Patel, Lead Advanced Therapies (Cell & Gene) Specialist Clinical Trial Pharmacist, Great Ormond Street Hospital for Children
Carolyn Chan, Senior Specialist Clinical Trials (ATIMPs) and QA Pharmacist, Great Ormond Street Hospital
Mar 1813:35
Conference pass
Development of viral plasmids for AAV manufacturing
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Piers Walser, Lead Development Scientist, Clinical Biotechnology Centre, NHSBT
Mar 1813:35
Conference pass
Ongoing research into Gene Therapy Standards
Gene Therapy (Track 7)
Claire Kerridge, Head of Gene Therapy, MHRA
Mar 1813:35
Conference pass
Panel Discussion: Autologous vs. Allogeneic Approaches
Gene Modified Cell Therapy (Track 8)
Mathias Kroll, Chief Business Officer, Cynata Therapeutics Ltd
Jiri Eitler, Group Leader - NK Cell Therapy, Dresden University of Technology
Mar 1813:35
Conference pass
Panel Discussion: Building the ATMP Workforce of the Future: Improving Skills, Diversity and Training
Innovation (Track 2)
Moderator: Anji Miller, Skills Lead, Innovation Hubs for Gene Therapies/Programme Director, Translational Skills, LifeArc
Nicola Ambler, Founder, The CGT Circle
Tanya Patel, Senior Manager CTSM, BioNTech
Katy Newton, Chief Scientific Officer, MFX
Manal Mohammed, Senior Lecturer (Medical Microbiology), University of Westminster
Mar 1813:35
Conference pass
Panel Discussion: How can the Uptake of Approved CAR-T Therapies be Improved: Addressing Supply Costs, Access and Other Barriers?
Cell Therapy Sponsored by LICORbio (Track 3)
Adam PARNABY, Lead, Global Policy & Access, Bristol Myers Squibb
Omer Dushek, Professor of Molecular Immunology, University of Oxford
Mar 1813:35
Conference pass
Panel Discussion: Innovation In Gene Editing - Leveraging Platform Technology to Enhance Development Efficiency
Gene Editing (Track 5)
Moderator: Randolph Corteling, Chief Scientific Officer, ReNeuron
Claudio Mussolino, Group Leader - Genome and Epigenome Engineering, Freiburg University Medical Center
Roberto Nitsch, Director, AstraZeneca
Pia Johansson, Director, Cell and Gene Technologies Core, Lund University
Dominic Schmidt, General Partner, Advent Life Sciences
Tom Payne, Chief Operating Officer, Laverock Therapeutics
Cecile Bauche, Chief Scientific Officer, Alaya.bio
Mar 1813:35
Conference pass
Panel Discussion: Key Learnings for Successful Company Creation and Spinning Out
Start-ups Showcase (Track 6)
Moderator: Leigh Brody, Investor, AlbionVC
James Levine, President, Fondation Ipsen
Pamela Tranter, Head, Translational Research Group (TRO), University College London
Dominic O'Regan, Business Development Consultant & Investor, New Mosaic
Giovanni Rizzo, Partner Biotech Fund, Indaco Venture Partners
Mar 1813:35
Conference pass
Panel Discussion: Manufacturing Strategies: Decentralised Vs. Centralised Approaches for Cell Therapies
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Sarah Snykers, Head of Operations, Legend Biotech
Stephen Sullivan, Director, Lindville Bio
Urvi Thacker, Expert MSAT, Independent
Valentin von Werz, Post Doc Reseracher, TU Wien
Lilian Hook, Director of Cell, Apheresis and Gene Therapies, NHS Blood and Transplant
Lior Raviv, CTO, Pluri
Mar 1813:35
Conference pass
Panel Discussion: Navigating the Global Regulatory Landscape for Commercial Approval
Regulation (Track 1)
Moderator: Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Sean Russell, Head of Regulatory Affairs, Telethon Foundation
Amina Al-Mossawi, Qualified Person, MeiraGTx
Anna Koptina, Head Of Regulatory Affairs, Mendus
Janet Glassford, Expert Quality Assessor, Biologicals Unit, Medicines & Healthcare products Regulatory Agency
Kathryn Parsley, VP, Regulatory Affairs, Complement Therapeutics
Mar 1813:55
Conference pass
Designing next generation adsorbent materials for viral vector manufacturing
Gene Therapy (Track 7)
George Pamenter, Researcher, UCL
Mar 1813:55
Conference pass
Development of innovative in vivo CAR-T therapies: From the bench to the clinic
Clinical Development (Track 4)
Renaud Vaillant, CEO & co-Founder, Alaya.bio
Mar 1813:55
Conference pass
Lentiviral vector manufacturing
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Noor Mujahid, Head of Vector Process Development, NHS Centre for Cell Gene and Tissue Therapeutics
Mar 1814:15
Conference pass
Automated CAR-T manufacturing assisted by AI
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Laura Herbst, Group Manager, Fraunhofer-Institute for Production Technology
Julius Mathews, Group Manager, Fraunhofer Institute for Production Technology IPT
Mar 1814:15
Conference pass
CRISPR modification of NK cells
Gene Modified Cell Therapy (Track 8)
Steven Cox, Senior Postdoctoral Research Scientist in Immunotherapy, Anthony Nolan
Mar 1814:15
Conference pass
Curing blindness: Cell therapy for AMD
Cell Therapy Sponsored by LICORbio (Track 3)
Mar 1814:15
Conference pass
Enabling precision editing through modified CRISPR Cas systems
Gene Editing (Track 5)
Claudio Mussolino, Group Leader - Genome and Epigenome Engineering, Freiburg University Medical Center
Mar 1814:15
Conference pass
Perspectives from pharmacy: Accelerating clinical trials set-up and delivery
Clinical Development (Track 4)
Mar 1814:15
Conference pass
Standardisation for scientists in basic research in regenerative medicine
Regulation (Track 1)
Lyn Healy, Principal Scientist, The Francis Crick Institute
Mar 1814:15
Conference pass
Talent investor readiness for start-ups
Start-ups Showcase (Track 6)
Jason Beckwith, Professor, University of Dundee
Mar 1814:15
Conference pass
Unpicking AAV ocular inflammation to improve outcomes for gene therapy
Gene Therapy (Track 7)
Alison Clare, Senior Research Associate, University of Bristol
Mar 1814:15
Conference pass
Using lipid systems biology towards diagnostic and therapeutic gain
Innovation (Track 2)
Sheba Jarvis, Consultant Endocrinologist and Obstetric Physician, Imperial College London
Mar 1815:05
Conference pass
Chair's Remarks: Abdullah Khan, Radcliffe Department of Medicine Principal Investigator, MRC WIMM Research Fellow, University of Oxford
Innovation (Track 2)
Abdullah Khan, Radcliffe Department of Medicine Principal Investigator, MRC WIMM Research Fellow, University of Oxford
Mar 1815:05
Conference pass
Chair's Remarks: Claudiu Cozmescu, Postdoctoral Researcher, Gissen Lab, UCL
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Claudiu Cozmescu, Postdoctoral Researcher, Gissen Lab, University College London
Mar 1815:05
Conference pass
Chair's Remarks: Darius Widera, Professor of Stem Cell Biology and Regenerative Medicine, University of Reading
Cell Therapy Sponsored by LICORbio (Track 3)
Mar 1815:05
Conference pass
Chair's Remarks: Giandomenico Turchiano, Associate Director, Cell & Gene therapy Safety, AstraZeneca
Gene Editing (Track 5)
Giandomenico Turchiano, Associate Director, Cell & Gene therapy Safety, AstraZeneca
Mar 1815:05
Conference pass
Chair's Remarks: Giovanni Rizzo, Partner Biotech Fund, Indaco Venture Partners
Start-ups Showcase (Track 6)
Giovanni Rizzo, Partner Biotech Fund, Indaco Venture Partners
Mar 1815:05
Conference pass
Chair's Remarks: Heather Main, Co-founder, HOYA Consulting
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Heather Main, Co-Founder, HOYA Consulting
Mar 1815:05
Conference pass
Chair's Remarks: Marcello Maresca, Senior Director - Genome Engineering, AstraZeneca
Gene Modified Cell Therapy (Track 8)
Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca
Mar 1815:05
Conference pass
Chair's Remarks: Paul Gissen, Professor in Paediatric Metabolic Diseases, University College London and Great Ormond Street Hospital
Clinical Development (Track 4)
Mar 1815:05
Conference pass
Chair's Remarks: Sara Benedetti, Group Leader, Assistant Professor in Gene Therapy, UCL
Gene Therapy (Track 7)
Sara Benedetti, Group Leader, Assistant Professor in Gene Therapy, University College London
Mar 1815:05
Conference pass
Chair's Remarks: Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Regulation (Track 1)
Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Mar 1815:10
Conference pass
Assessing the clinical efficacy of immunotherapies using engineered human model systems
Innovation (Track 2)
Abdullah Khan, Radcliffe Department of Medicine Principal Investigator, MRC WIMM Research Fellow, University of Oxford
Mar 1815:10
Conference pass
Breaking Free from Viruses: Developing a Scalable Non-Viral Platform for HSC Gene Therapy Using CRISPR/Cas9 and Sleeping Beauty Transposon Delivered via Nucleofection or Lipid Nanoparticles
Gene Therapy (Track 7)
Mar 1815:10
Conference pass
Decentralised CAR-T manufacturing
Cell Therapy Sponsored by LICORbio (Track 3)
Lilian Hook, Director of Cell, Apheresis and Gene Therapies, NHS Blood and Transplant
Mar 1815:10
Conference pass
Diagnosing and addressing manufacturing bottle necks
Start-ups Showcase (Track 6)
Mar 1815:10
Conference pass
Engineering next generation T-cells for cancer immunotherapy
Gene Modified Cell Therapy (Track 8)
Mar 1815:10
Conference pass
Genomic stability and DNA repair after gene editing
Gene Editing (Track 5)
Giandomenico Turchiano, Associate Director, Cell & Gene therapy Safety, AstraZeneca
Mar 1815:10
Conference pass
In vivo lentiviral gene therapy for cholestatic disorders
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Claudiu Cozmescu, Postdoctoral Researcher, Gissen Lab, University College London
Mar 1815:10
Conference pass
Latest update on EU policies for ATMP development
Regulation (Track 1)
Giulia Leonetti, Policy Officer, European Commission
Mar 1815:10
Conference pass
Panel Discussion: Considerations for Successful Clinical Trial Design
Clinical Development (Track 4)
Sonia Valero, Head Of Clinical Operations - Patient Advocacy Leader, Vivet Therapeutics
Roger Legtenberg, Co-Founder, Partners4Patients Foundation
Carolyn Chan, Senior Specialist Clinical Trials (ATIMPs) and QA Pharmacist, Great Ormond Street Hospital
Victor Hernandez, CSO, Axovia therapeutics
Julien Baruteau, MRC Clinician Scientist Fellow and Group Leader, Great Ormond Street Hospital/University College London
Mar 1815:10
Conference pass
Process development and intensification of NK cell production in stirred tank bioreactors
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Valentin von Werz, Post Doc Reseracher, TU Wien
Mar 1815:30
Conference pass
Developing a perfusion process for lentiviral vector manufacturing
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Marta Arrizabalaga Cascallana, PhD Researcher, UCL
Mar 1815:30
Conference pass
From academic research to innovative ideas: Turning research into meaningful results
Innovation (Track 2)
Mar 1815:30
Conference pass
Gene editing to the retina: From in vivo to 3D retinal organoids
Gene Editing (Track 5)
Juliette Pulman, Research Fellow, INSERM
Mar 1815:30
Conference pass
Going further: Cynata’s pursuit of developing potent regenerative cell therapies for global use
Cell Therapy Sponsored by LICORbio (Track 3)
Mathias Kroll, Chief Business Officer, Cynata Therapeutics Ltd
Mar 1815:30
Conference pass
Programmable gene silencing technology for next-generation advanced therapy development
Gene Modified Cell Therapy (Track 8)
Tom Payne, Chief Operating Officer, Laverock Therapeutics
Mar 1815:30
Conference pass
Targeting the blood-brain barrier to improve CNS delivery of hematopoietic stem cell gene therapy for metabolic disorders
Gene Therapy (Track 7)
Sara Benedetti, Group Leader, Assistant Professor in Gene Therapy, University College London
Mar 1815:30
Conference pass
The Latest Developments in Regulation for Advanced Therapy Medicinal Products
Regulation (Track 1)
Anna Koptina, Head Of Regulatory Affairs, Mendus
Mar 1815:30
Conference pass
The need for bespoke quality analytics in developing iPS cell therapeutics
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Stephen Sullivan, Director, Lindville Bio
Mar 1815:30
Conference pass
Using AI to develop personalised cancer vaccines
Start-ups Showcase (Track 6)
Prasun Chakraborty, Founder & CEO, Genevation LTD
Mar 1815:50
Conference pass
AAV gene therapies: Solving the challenge of neutralising antibodies
Start-ups Showcase (Track 6)
George Frodsham, Founder & CEO, MediSieve Limited
Mar 1815:50
Conference pass
Accelerating the discovery of novel CAR-T
Clinical Development (Track 4)
Mar 1815:50
Conference pass
AI-Driven Excellence in GMP Manufacturing: Transforming Quality and Operations
Innovation (Track 2)
Owen Bain, Director, Centre for Cell Gene Tissue Therapeutics, Royal Free NHS Trust
Mar 1815:50
Conference pass
Error-free genome editing for eradication of life-threatening persistent virus infections
Gene Editing (Track 5)
Mar 1815:50
Conference pass
Latest insight from King’s College London Gene Therapy Vector Facility
Viral Vector Manufacturing Sponsored by Fujifilm Biotechnologies (Track 9)
Simon Walker, Head of MSAT, Gene Therapy Vector Facility, Kings College London
Mar 1815:50
Conference pass
Leveraging technological innovation to support allogenic manufacturing
Cell Therapy Manufacturing Sponsored by MasterControl (Track 10)
Lior Raviv, CTO, Pluri
Mar 1815:50
Conference pass
Optimising the antigen sensitivity of CAR-T cells
Cell Therapy Sponsored by LICORbio (Track 3)
Omer Dushek, Professor of Molecular Immunology, University of Oxford
Mar 1815:50
Conference pass
Requirements for Governance and Preparation of Gene Therapy
Gene Therapy (Track 7)
Nicola Stoner, Consultant Pharmacist - Cancer & ATMPs, Oxford University Hospitals NHS Foundation Trust
Mar 1815:50
Conference pass
The Importance of Interacting with Regulators
Regulation (Track 1)
last published: 02/Feb/26 16:35 GMT
Get Involved with Advanced Therapies Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events